Title : Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor.

Pub. Date : 2019

PMID : 30569877






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metformin has demonstrated its ability to inhibit cell growth and the LY294002 is the major inhibitor of PI3K/AKT/mTOR pathway that has antiangiogenic properties. Metformin mechanistic target of rapamycin kinase Canis lupus familiaris
2 Metformin has demonstrated its ability to inhibit cell growth and the LY294002 is the major inhibitor of PI3K/AKT/mTOR pathway that has antiangiogenic properties. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one mechanistic target of rapamycin kinase Canis lupus familiaris